Clario leads the conversations on decentralized clinical trials (DCTs) and diversity in clinical research at DIA 2022
Industry thought leaders collaborate on using technology to make clinical research more efficient, inclusive and sustainable
- Clario to host interactive Innovation Theatre session, Decentralized Clinical Trials: Real Solutions in Real-Time
- Clario’s Dr. Lindsay Hughes to present poster, BYOD VS Provisioned Devices: A Cross-Study Exploration of Factors Influencing Patient Compliance
- Attendees can contribute to research on diversity in clinical trials by completing a survey at Clario booth #1831
PHILADELPHIA, PA – June 17, 2022 – Clario, the global leader in evidence-generation technology for hybrid, decentralized and site-based clinical trials, announced today that it will be leading discussions on how to optimize decentralized clinical trials (DCTs) and achieve diversity and equity in clinical research at the DIA 2022 Global Annual Meeting. The output of the thought leadership exercises will be recommendations for using technology to enable efficiency and sustainability in clinical research.
DCTs and diversity are two of the most prominent topics in the life sciences community today, and as such, will be cornerstone subjects at this year’s DIA conference, one of the industry’s top forums for the exchange of ideas to further scientific and medical innovations. Clario will drive the conversation forward and advance collaboration through an interactive Innovation Theatre session, a poster presentation and by surveying conference attendees throughout the event.
“This is a pivotal time for clinical scientists and innovators, as we are in a position to resolve challenges that have plagued clinical research for years,” said Matt McCarty, Chief Strategy and Marketing Officer at Clario.
“We are excited to convene multiple experts with different perspectives to discuss the benefits and challenges of DCTs. We will also champion awareness of the lack of diversity in clinical trials and explore options for increasing equity and inclusivity, not just for the sake of safety and efficacy, but because it’s simply the right thing to do.”
The Clario-hosted Innovation Theatre session, Decentralized Clinical Trials: Real Solutions in Real-Time, will take place Tuesday, June 21, 2022, 10:20 – 10:50 a.m., at the McCormack Place Exhibit Hall Theater #2. Audience members will be polled in real-time on pressing DCT-related issues such as evolving roles for patients, sites and investigators, regulatory factors and diversity and a panel of key opinion leaders will immediately react to the findings. The panel participants are:
- Jen Horonjeff
Patient Advocate; Founder and Chief Executive Officer, Savvy Cooperative
Panelist – United States
- Craig Lipset
Co-Chair, Decentralized Trials & Research Alliance (DTRA)
Panelist – United States
- Bryan McDowell
Vice President, eCOA Clinical Science & Consulting, Clario
Panelist – Switzerland
- Matthew McCarty
Chief Strategy & Marketing Officer, Clario
Moderator – United Kingdom
In support of improving diversity in clinical trials, Clario will conduct on-site research. Any DIA conference participant may visit the Clario exhibit, #1831, and share insights by taking a short survey on diversity in clinical trials. The results of Clario’s research will be made available following the conference.
Decentralized clinical trials necessitate remote data capture using devices. In Poster Session II on June 21, 2022 from 12:00 – 1:15 p.m., Dr. Lindsay Hughes, Clario Principal Scientific Advisor, will present valuable research with her poster, BYOD VS Provisioned Devices: A Cross-Study Exploration of Factors Influencing Patient Compliance.
Clario is a leading technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized and site-based trials, our deep scientific expertise, global scale, and the broadest endpoint technology platform in the industry, allows our partners to transform lives. Clario’s solutions have been powering hybrid and decentralized clinical trials (DCT) for over 15 years, enabling sponsors to collect high-quality endpoint data from any modality or location, all while improving the patient experience and diversity. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion and respiratory endpoints. With 30 facilities in nine countries, Clario’s global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory for over 5m patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.
Clario Media Contact
Sr. Director, Corporate Communications